Loading
Latest filing published 13 Nov 2009 for GTC BIOTHERAPEUTICS INC, €13k.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Harry Meade is a declared insider of GTC Biotherapeutics Inc, with filings sourced from SEC (Form 4). Between 10 March 2006 and 2 November 2009, the trades on record add up to 10 filings.
Every open-market trade on record is a purchase: 1 purchase worth €6,234, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 9 share grants.
The latest filing, published on 13 November 2009, reports a share grant of €4,521 in GTC Biotherapeutics Inc. The clock since the last published purchase (14 December 2007) now reads 6,888 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations